A B S T R AC T
Background. Kidney transplantation increases the chances for pregnancy and live birth for women with end-stage kidney disease. The aims of this study were to describe the outcomes of pregnancies in women with a kidney transplant and to evaluate the impact on anti-human leucocyte antigen (HLA) alloimmunization. Methods. We analysed 61 pregnancies that occurred in 46 patients after having excluded 10 miscarriages during the first trimester and 10 other pregnancies from which important data were missing. Anti-HLA antibodies were screened using the Luminex assay.
Results. Overall, the live birth rate was 83% (94% after exclusion of miscarriages during the first trimester). Pre-eclampsia and gestational diabetes occurred in 26 and 21% of cases, respectively. The use of tacrolimus was an independent predictive factor for gestational diabetes. Twenty-four newborns (42%) were premature (<37 weeks). The median birth weight was 2720 (1040-3730) g. Nine newborns (15%) had low birth weights (<2.5 kg). At least one severe complication occurred in 56% of pregnancies. A high glomerular-filtration rate (GFR) before pregnancy was the sole independent protective factor that avoided a severe complication. Death-censored kidneyallograft survival was 80.4% at 6 years. De novo donor-specific anti-HLA antibodies were detected after only 5.9% of pregnancies: for two women, the father had the same HLA antigens as those from the deceased organ donor. The determination of the HLA of the father before pregnancy can better inform the woman about the possible impact of pregnancy on her kidneyallograft function. Conclusions. Despite many complications, the outcomes for pregnancy and kidney allografts are good. The risk of anti-HLA alloimmunization was low.
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I N T RO D U C T I O N
Pregnancy in women on dialysis is rare and is reported to be associated with significant maternal and fetal morbidity and mortality [1] . Kidney transplantation is the method of choice for treating end-stage kidney disease as it improves patient survival and quality of life [2] . In addition, it increases women's chances of becoming pregnant and of a live birth [3] .
Because the universal use of the Luminex ® single-antigen (SA) assay, the role of anti-human leucocyte antigen (HLA) antibodies after kidney transplantation has been well characterized. The development of anti-HLA antibodies is mainly caused by previous transplantation, blood transfusion and previous pregnancy [4] . Donor-specific anti-HLA antibodies (DSAs) are responsible for antibody-mediated rejection and reduced kidney-allograft survival [5] . After pregnancy, women may develop anti-HLA antibodies after having encountered inherited HLA antigens from the father of the fetus. However, it is unknown whether women can develop anti-HLA antibodies when pregnancy occurs after kidney transplantation and while they are receiving immunosuppressive therapy.
The aims of this retrospective single-centre study were to describe the outcomes of pregnancies in women with a kidney transplant and to evaluate the impact on anti-HLA alloimmunization.
M AT E R I A L S A N D M E T H O D S
Between 1969 and December 2011, 567 women, aged between 18 and 45 years, have received a kidney transplant in our institution. Within this period, 81 pregnancies occurred in 63 women with a kidney transplant (11.1%). Eight patients who had 10 pregnancies and who had miscarried during the first trimester were not included in the study. Nine patients (who had 10 pregnancies) were excluded from the study because of missing data. Hence, 61 pregnancies that occurred in 46 patients were analysed.
Classical demographic and clinical data were collected from chart reviews. Anti-HLA antibodies and DSAs were assessed before and after pregnancy. We also assessed maternal and fetal complications, i.e. late miscarriage during the second or third trimester, pre-eclampsia (hypertension and proteinuria/creatininuria >0.3 g/g, or kidney-function impairment and hypertension, or an ischaemic placenta on pathological examination), gestational diabetes, fetal malformations, preterm birth (<37 weeks of gestation) and low birth weight (<2.5 kg). Late miscarriage, preeclampsia, fetal malformations, preterm birth and a low birth weight were considered to be severe complications.
Anti-HLA antibody analyses
The Luminex ® (SA) assay was set up in our institution in February 2008. Hence, patients who started gestation after February 2008 were tested using the Luminex (SA) assay before and after pregnancy.
For those who began their pregnancy before February 2008, and if anti-HLA antibodies were not detected before the beginning of the pregnancy using a low-sensitivity assay, and if they were still negative after February 2008 without having received any specific anti-antibody-mediated rejection therapy ( plasmapheresis, rituximab, intravenous immunoglobulin or bortezomib), the patients were considered to be non-sensitized. Conversely, those who began their pregnancy before February 2008, and who had detectable anti-HLA antibodies before pregnancy using a low-sensitivity assay, were not considered in this analysis. Similarly, we have excluded data from patients who had detectable anti-HLA antibodies after pregnancy if the pre-pregnancy sample was not analysed using the Luminex (SA) assay.
The Luminex ® (SA) assays determined the specificity of class-I HLAs in A/B and class-II HLAs in DR/DQ immunoglobulin G (IgG) antibodies in the recipients' sera (centrifuged at 10 000 g for 10 min) using Labscreen single-Ag HLA class-I and class-II detection tests (One Lambda, Canoga Park, CA), according to the manufacturer's instructions. The presence and specificity of antibodies were then detected using a Labscan 100 ® , and the mean fluorescence (baseline value) for each sample in each bead was evaluated. The baseline value was calculated as follows: [raw sample mean fluorescence intensity (MFI) − raw negative serum control MFI] − (negative-bead raw MFI with sample − negative-bead raw MFI with negative serum control). A baseline value of >1000 was considered positive.
Statistical analyses
Reported values are shown as the mean (±SD) or median (ranges). Proportions were compared using Fisher's exact test. Quantitative variables were compared using the non-parametric Friedman test for repeat measurements, the Wilcoxon test or Student's t-test. The predictive factors for developing a severe complication, and the predictive factors for developing gestational diabetes in pre-pregnancy non-diabetic women, were determined by univariate and multivariate regression analyses. Factors associated, by univariate analyses (at a significance of P < 0.05), with the development of a severe complication or with the development of gestational diabetes were selected for multivariate analyses. A P-value of <0.05 was considered statistically significant.
R E S U LT S

Patient characteristics
Forty-six patients who had 61 pregnancies during the study period were analysed (Table 1) . Further, 33, 11 and 2 patients had one, two or three pregnancies, respectively. Two of the 46 patients had received a dual transplantation: one simultaneous pancreas-kidney transplantation and one combined liver-kidney transplantation. Thirty-nine women (85%) were recipients of a first kidney transplant, six patients were recipients of a second kidney transplant and only one patient had received a third kidney transplant. The indications for kidney transplantation were glomerular disease in 24 patients (52%), urological or tubulointerstitial disease in 16 patients (35%), unknown in 5 patients (11%) and vascular in 1 patient (2%).
Evolution and outcomes of pregnancies
Overall, 67 of the 81 pregnancies (83%) resulted in a live birth ( Table 2 ).
Outcome of pregnancies that occurred in patients excluded from the study for missing data (n = 10). All 10 pregnancies resulted in a live birth (100%). Pre-eclampsia occurred in four cases (25%). One patient developed a severe infection, i.e. chorioamnionitis. The median gestational term was 36 (range: 32-38) weeks. Five newborns (50%) were premature (<37 weeks). Of these, none had a severe prematurity (<32 weeks). Delivery was done by caesarean in all cases. The median birth weight was 2250 (range: 1350-2730) g. No neonatal deaths occurred ( Figure 1 ).
Outcome of pregnancies that occurred in patients included in the study (n = 61). In the large majority of cases (89%), the pregnancy was planned. In these cases, mycophenolic acid was replaced by azathioprine before conception. In addition, 21 patients (34%) had undergone a kidney biopsy before the immunosuppressants were modified in order to eliminate subclinical rejection. In seven other cases pregnancy was not planned, but only one of these women was receiving mycophenolic acid at conception. None was given mammalian targetof-rapamycin (mTOR) inhibitors at conception or during the pregnancy. During pregnancy, 24 women (39%) were given aspirin.
Fifty-seven of the 61 pregnancies (93%) resulted in a live birth, of which two patients gave birth to twins. Of the four non-live births, one patient miscarried during the third trimester after a car accident. For the other three cases, pregnancy was interrupted during the second trimester because of severe fetal malformations, i.e. one trisomy 18, one isolated heart malformation and one heart and lung malformation, which occurred in the patient who was receiving mycophenolic acid at conception.
No complications occurred among 31 of the 57 pregnancies that led to a live birth (54%). Pre-eclampsia occurred in 16 cases (26%), gestational diabetes in 13 cases (21%), an infection in 14 cases (23%), a threat of premature delivery in 10 cases (16%) and intrauterine growth retardation in 9 cases (15%) ( Table 2 ). Only one patient developed a severe infection, i.e. chorioamnionitis. Regarding aspirin intake, pre-eclampsia occurred in 25% of the women who took aspirin compared with 27% of women who did not (P = ns). The incidence of gestational diabetes was significantly higher in patients receiving tacrolimus compared with those given cyclosporine A (35 versus 7.7%, P = 0.02, and 35 versus 4%, P = 0.007 [if the prepregnancy diabetic patient is excluded]). Predictive factors for gestational diabetes were looked for in pre-pregnancy non-diabetic patients (Supplementary Table S1 ). The use of tacrolimus rather than cyclosporine A was to solely predictive factor for gestational diabetes: odds ratio (OR) 12.6, 95% confidence interval (CI) 1.5-105, P = 0.02. The median gestational term was 37 (range: 29-39) weeks. Twenty-four newborns (42%) were premature (<37 weeks). Of these, five had severe prematurity (<32 weeks). An induced delivery was required in 70% of cases and delivery was done by caesarean in 67% of these cases.
In four cases (7%), a haemorrhage occurred at delivery. One patient died at 1 month after delivery from rupture of a cerebral aneurysm.
Fifty-nine babies were born from the 57 pregnancies, as two patients gave birth to twins. The median birth weight was 2720 (range: 1040-3730) g. Nine newborns (15%) had low birth weights (<2.5 kg). No neonatal deaths occurred. Three malformations were diagnosed during the neonatal period: one trisomy 21, one pyloric stenosis and one hepatic arteriovenous fistula. In both pregnancies that resulted in twins, the newborns were premature and had low birth weights.
Risk factors for a severe complication during pregnancy At least one severe complication, i.e. a late miscarriage, and/or pre-eclampsia, and/or fetal malformation, and/or preterm birth and/or a low birth weight, occurred in 34 of the 61 pregnancies (56%). Comparisons of the pregnancies with and without a severe complication were assessed from the mean in univariate analyses (Table 3) . A lower glomerularfiltration rate (GFR) before and during pregnancy, as well as a higher systolic blood pressure and a significantly higher proteinuria level, occurred during the third trimester in patients who experienced a more severe complication. Because the two last parameters are the result of pre-eclampsia and because they occur late during pregnancy, they were not included in the multivariate analyses. Hence, only kidney function before pregnancy was included in the multivariate analyses model. A high GFR before pregnancy was the sole independent protective factor of a severe complication: OR (for every mL/min/1.73 m 2 of GFR) 0.97, 95% CI 0.94-0.99, P = 0.03.
Outcomes of kidney-allograft parameters
As shown in Figure 2A , the mean GFR remained relatively stable during pregnancy and until 1 year after delivery. Before conception, 85% of patients had a proteinuria/creatininuria index of <0.3 g/g. At delivery, 60% of patients had significant proteinuria (proteinuria/creatininuria index >0.3 g/g). Nevertheless, proteinuria disappeared in the majority of patients after delivery ( Figure 2B ). At delivery, eight women (14%) had a nephrotic syndrome. Systolic blood pressure significantly increased during pregnancy, especially during the third trimester, and remained higher at 1 year after delivery when compared with pre-conception rates ( Figure 2C ). This required an increase in the number of anti-hypertensive drugs from zero (0-4) before pregnancy, to one (0-3) at delivery (P = 0.02) and at 1 year later (P = 0.03). Interestingly, no significant change in diastolic blood pressure was observed. During pregnancy, haemoglobin level decreased significantly until delivery and then increased thereafter ( Figure 2D ). The number of patients requiring erythropoietin support increased from 9% before pregnancy to 22% at delivery (P = 0.07). No case of acute rejection was observed during pregnancy.
At the last follow-up, i.e. 6 years (2 months-25 years) after pregnancy, 35 of the 46 patients still had a functioning graft (76%). Death-censored kidney-allograft survival was 80.4%. Hence, overall, 11 women had lost their graft function after a median time of 14 (5-22) years post-transplantation, and a 
O R I G I N A L A R T I C L E
P r e g n a n c y a n d k i d n e y t r a n s p l a n t a t i o n median time of 6 years (1 month-18 years) after delivery. Three graft losses were observed within the year following delivery: one woman developed a thrombotic microangiopathy immediately after delivery; another, who had poor kidney function before the pregnancy (GFR 44 mL/min, proteinuria/ creatininuria 0.3 g/g) and severe grade-III interstitial fibrosis tubular atrophy (IFTA), evolved to end-stage kidney disease; the third woman died with a functioning graft (see above). Eight other graft losses were observed after the first year after delivery: these were from IFTA (n = 6), immunoglobulin (Ig)-A nephropathy relapse (n = 1) and death with functioning graft (n = 1). The majority of these patients had persistent proteinuria after delivery.
Immunological follow-up
We have assessed the immunological profiles before and after 60 pregnancies (Figure 3) . We have excluded the data from the patient who died soon after delivery. Before pregnancy, no anti-HLA antibodies were detected in 44 cases (73%) using the low-sensitivity assay or the Luminex SA assay. Before pregnancy, 2 out of these 44 non-anti-HLA sensitized patients had undergone previous kidney transplantation, 8 had experienced a previous pregnancy and 15 patients had received a blood transfusion. At 1 year after pregnancy and/or afterwards, 42 women were tested using the Luminex assay and still did not have detectable anti-HLA antibodies. Conversely, two remaining cases who had no detectable anti-HLA 12.8 ± 1. antibodies before transplantation using the Luminex SA assay, had developed de novo DSAs at 2 and 3 months post-delivery. In both cases, the MFI of the DSAs was at 3000. Before transplantation, anti-HLA antibodies were detected in the 16 remaining cases (27%). Of these, nine did not have a complete follow-up with the Luminex assay before and after pregnancy and thus were consequently excluded from the analyses. In contrast, the seven other cases had an exclusive follow-up using the Luminex assay. One of these seven cases developed de novo DSA at 3 months after delivery. The MFI of the DSA was 13 000. The immunization profile did not change for the other six cases. Hence, de novo DSAs were detected after three
Outcomes of (A) kidney function, (B) proteinuria levels, (C) systolic blood pressure and (D) haemoglobin levels before, during and after pregnancy. Data are presented as mean ± standard deviation.
F I G U R E 3 : Immunological follow-up before and after pregnancy. anti-HLA Ab, anti-human leucocyte antigen antibodies; DSA, donorspecific antibodies.
O R I G I N A L A R T I C L E
P r e g n a n c y a n d k i d n e y t r a n s p l a n t a t i o n of the 51 pregnancies that were monitored using the Luminex assay (5.9%). HLA typing of the father of the newborn was obtained for two of the three patients who developed de novo DSAs. Interestingly, in both cases, the father had a shared HLA subtype with the deceased organ donor. DSAs were detected in routine assessments at 2, 3 and 3 months post-delivery. None of these three patients had received any specific anti-DSA therapy. In one of the two initially non-sensitized patients, GFR declined from 48 mL/min before pregnancy to 15 mL/min at the last follow-up, i.e. 18 months after delivery. In the second woman, kidney function declined progressively. Kidney biopsies, performed at 3 and 5 years after the appearance of DSAs, showed features of chronic antibody-mediated rejection. In this woman, loss of allograft function occurred at 5 years after delivery and at 14 years after transplantation. The third woman, who was initially anti-HLA sensitized and who developed de novo DSA at 3 months after delivery, did not have a decline in kidney function. A kidney biopsy showed no signs of active antibody-mediated rejection. During a subsequent pregnancy, she also did not present with any severe complications. Her kidney function at 4 years after the first pregnancy and at 2 years after the second pregnancy remains similar to that observed before the first pregnancy, i.e. GFR ∼50 mL/min and a proteinuria/creatininuria level of 0.4 g/g.
D I S C U S S I O N
The first cases to be described of pregnancy in women who had received a kidney allograft were reported in 1963 by Murray et al. [6] . Thereafter, a large number of pregnancies have been published. Nevertheless, pregnancy in the transplant population is still not well documented. Herein, we report on our single-centre experience. Our findings were 6-fold: (i) the overall live birth rate was 83%; (ii) even though >50% of pregnancies were associated with a severe complication, the patients' and newborns' outcomes were good; (iii) a low GFR before pregnancy was the sole predictive factor for a severe complication; (iv) 76% of patients had a functioning kidney allograft after a median time of 6 years (2 months-25 years) after pregnancy; (v) the use of tacrolimus rather cyclosporine A was an independent predictive factor for gestational diabetes and (vi) for the first time, we have shown that, using the Luminex (SA) assay, only 6% of patients developed DSAs after pregnancy.
The overall live birth rate was good (83%). After excluding miscarriages during the first trimester, the live birth rate was 94% and similar to that observed in a UK cohort (91%) [7] , and it was somewhat higher than the data reported in registry studies, i.e. 76.9% for the ANZDATA registry [8, 9] , 70.8-76% in the US National Transplantation Pregnancy Registry (NTPR) [10] and 79% in the UK National Cohort study [11] . The difference between our results and these registry studies is probably related to the lack of completeness in collecting data on early spontaneous abortions of patients who had miscarried during the first trimester of pregnancy in this study. In a review paper by Richman and Gohh [12] , the live birth rates reported in single-centre studies range from 43.2 to 85.7%.
Very recently, in a large cohort, Wyld et al. [9] compared pregnancy outcomes for kidney-transplant recipients with those of the Australian general population. Compared with the general population, the live birth rate was lower (76 versus 99.3%), the mean gestational age was shorter (35 ± 5 versus 39 weeks) and the mean live birth weight was lower (2485 ± 783 versus 3358 ± 2 g) in the transplant population. The authors concluded that, although pregnancies in women with a transplant are generally successful, outcomes differ from the general population, despite good kidney function [9] .
In our study, the proportions of premature, low birth weight and women who required a caesarean were 42, 15 and 67%, respectively. These data are similar to the previous data reported from registry and single-centre studies [12] . Six cases of malformation were observed: three during pregnancy, which required a therapeutic abortion. For the other three cases, malformation diagnosis was done after delivery. Of note, one of the malformations occurred in a women who began a non-planned pregnancy when she was still receiving mycophenolic acid. The use of mycophenolic acid and mTOR inhibitors has been associated with a high rate of malformations [10, 13, 14] . Therefore, it is recommended to stop these drugs before conception.
The incidence of gestational diabetes in our study was 21%, which is higher than that in previous reports [15] . This higher incidence may be related to different definitions and screening tools for gestational diabetes, as well as the type of immunosuppressive regimen. Indeed, 53% of our patients were given tacrolimus and the large majority received steroids (89%). We found that the incidence of gestational diabetes was significantly higher in patients given tacrolimus (35%) compared with those on cyclosporine A (7.7%), and the use of tacrolimus was an independent predictive factor for gestational diabetes. Tacrolimus has been identified as an independent predictive factor for new-onset diabetes mellitus after kidney transplantation [16, 17] . However, no association between the use of tacrolimus and gestational diabetes has been reported in the setting of kidney transplantation previously. Conversely, the incidence of gestational diabetes was higher in liver-transplant patients receiving tacrolimus (15%) compared with those given cyclosporine A (2%) [10] . Hence, in women at high risk of diabetes, e.g. high body-mass index, with a history of postgestational diabetes, it seems reasonable to prefer cyclosporine A to tacrolimus.
A severe complication, i.e. late miscarriage, pre-eclampsia, fetal malformation, preterm birth or a low birth weight, occurred in 55% of pregnancies. A low GFR before pregnancy was the sole independent predictive factor for the occurrence of a severe complication. Bramham et al. [11] found that women with more than two previous transplantations and with a lower creatinine level before pregnancy and during each trimester had poor pregnancy outcomes. The use of aspirin has been shown to reduce the risk of pre-eclampsia in highrisk patients [18] . However, this finding has not been confirmed in kidney-transplant patients. In this study, similar to a previous report [11] , the use of aspirin was not associated with less pre-eclampsia.
As previously reported [10, 11] , no significant deterioration in kidney function or case of acute rejection has been observed during pregnancy. After a median follow-up of 6 years, kidneyallograft survival and death-censored kidney-allograft survival were 76 and 80.4%, respectively. IFTA was the main cause of persisting proteinuria after delivery and graft loss.
In the literature, the rate of graft loss at 1 year after pregnancy ranges between 0 and 8.6% [12] . Levidiotis et al. [8] have reported similar death-censored kidney-allograft survival rates in pregnant and non-pregnant women, i.e. around 85% at 10 years. Coscia et al. [10] found that rejection during and at 3 months after pregnancy as well as creatinine level were independent predictive factors for graft loss at 5 years. In this latter study, the results for screening for anti-HLA antibodies during and after pregnancy are not reported.
In our study, we have assessed, for the first time, using the Luminex (SA) assay, the risk of developing DSAs during and until 1 year after pregnancy. DSAs were detected after 3 of 51 pregnancies (5.9%). Of great interest, we were able to obtain the HLAs of the fathers in two cases. In both cases, the father had the same HLA antigens as the deceased organ donor. This is an important finding as it shows that the development of anti-HLA antibodies during pregnancy is not common in kidney-transplant patients, but it also shows that determination of the HLA of the father before pregnancy can better inform the woman about the possible impact of pregnancy on her kidney-allograft function and could improve immunosuppression during pregnancy.
This study has several limitations. It is a retrospective, singlecentre study that included a relatively low number of patients. Nevertheless, it includes a homogenous group that was managed by nephrologists in close conjunction with high-risk obstetricians. Another limitation is the lack of follow-up for all patients who had the Luminex (SA) test, i.e. several pregnancies occurred several years before the use of the Luminex (SA) assay. Thus, it was not possible to test all patients. However, a large number of samples were studied with this very sensitive test. Finally, we did not compare the results obtained in our pregnant women group with a control group of non-pregnant women recipients. Nevertheless, previous registry studies reported death-censored kidneyallograft survival rates in pregnant and non-pregnant women [8] .
In summary, despite the large number of complications, the outcomes of the pregnancies were good in women with a kidney transplant, especially when GFR before pregnancy was high. The outcomes of kidney allografts were also good. In addition, the risk of anti-HLA alloimmunization was low. However, further studies are required to confirm this latter finding.
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